Have a personal or library account? Click to login
Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis Cover

Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis

Pneumologia
Volume 72 (2023): Issue 1 (January 2023)
By: Victoria Țau,  Andreea Zabară Antal,  Paula Vasilache Antohi,  Ioana Adelina Stoian,  Adriana Loredana Pintilie,  Antigona Carmen Trofor and  Radu Adrian Crișan-Dabija  
Open Access
|Jun 2024

Metrics

DOI: https://doi.org/10.2478/pneum-2024-0014 | Journal eISSN: 2247-059X | Journal ISSN: 2067-2993
Journal RSS Feed
Language: English
Page range: 90 - 96
Published on: Jun 19, 2024
Published by: Romanian Society of Pneumology
In partnership with: Paradigm Publishing Services
Publication frequency: Volume open
Keywords:
Coronavirus,
lung fibrosis,
Immune response,
Respiratory syndrome,
anti-fibrotic agent,
Nintedanib
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Internal medicine,
Pneumology

© 2024 Victoria Țau, Andreea Zabară Antal, Paula Vasilache Antohi, Ioana Adelina Stoian, Adriana Loredana Pintilie, Antigona Carmen Trofor, Radu Adrian Crișan-Dabija, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 72 (2023): Issue 1 (January 2023)Next article